Volume 1.41 | Oct 29

Prostate Cell News 1.41, October 29, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

DLC1 Negatively Regulates Angiogenesis in a Paracrine Fashion
In this study, researchers silenced Rho GTPase-activating protein DLC1 in nonmalignant prostate epithelial cells to explore its tumor suppression functions. The results strongly suggest that loss of DLC1 may serve as a “second hit” in promoting angiogenesis in a paracrine fashion during tumorigenesis. [Cancer Res]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies
 
 
WATCH THE VIDEO STEMCELL Technologies Inc
 



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]

Follow us on Twitter! @ProstateCell



SCIENCE NEWS

Too Much SP2 Protein Turns Stem Cells Into “Evil Twin” Tumor-forming Cancer Cells
Researchers have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. [Press release from North Carolina State University discussing online prepublication in Cancer Research]

Aspirin Use Associated With Lower Risk of Cancer Death for Men with Prostate Cancer
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study. [Press release from the American Society for Radiation Oncology (ASTRO) discussing data presented at the 52nd Annual Meeting of the ASTRO in San Diego]

Prostate Cancer Screening Improves Quality of Life by Catching Disease Before It Spreads
Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment, compared to men who were treated prior to the use of routine screening, according to the first study-of-its-kind. [Press release from the American Society for Radiation Oncology (ASTRO) discussing data presented at the 52nd Annual Meeting of the ASTRO in San Diego]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies

 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Overexpression of Transcription Factor Sp2 Inhibits Epidermal Differentiation and Increases Susceptibility to Wound- and Carcinogen-Induced Tumorigenesis
Here, researchers report that Sp2 protein abundance in mice increases in concert with the progression of carcinogen-induced murine squamous cell carcinomas. [Cancer Res]

WNT11 Expression Is Induced by Estrogen-Related Receptor Alpha and Beta-Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration
Specifically, using conditioned medium from cells overexpressing recombinant WNT11 or WNT11 neutralizing antibodies, researchers were able to show that this protein was the key mediator of the promigratory activities of estrogen-related receptor alpha/beta-catenin. [Cancer Res]

DNA Damage Recognition via Activated ATM and p53 Pathway in Nonproliferating Human Prostate Tissue
Here, researchers assess, using ex vivo cultures of human prostate tissue, DNA damage response caused by cytotoxic drugs (camptothecin, doxorubicin, etoposide, and cisplatin) and ionizing radiation in the context of normal tissue architecture. [Cancer Res]

Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies. Inhibition of Metastatic Tumor Growth in Severe Combined Immunodeficiency Mice
The data suggest that localized delivery of high dosages of epigallocatechin-3-gallate combined with low levels of doxorubicin may have significant clinical application in the treatment of metastatic prostate and/or eradication of primary tumors derived from tumor-initiating cells. [Am J Pathol]

Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion
Deregulation of both ErbB-2 signaling and matriptase activity has been associated with human prostate cancer (PCa) progression. In this communication, researchers investigated the roles of both ErbB-2 signaling in matriptase zymogen activation and matriptase in ErbB-2-induced PCa malignancy. [Am J Pathol]

Testing Mutual Exclusivity of ETS Rearranged Prostate Cancer
The issue of multifocality and interfocal heterogeneity is important and has not been fully elucidated due to lack of the systematic evaluation of E26 transformation specific (ETS) rearrangements in multiple tumor sites. The current study investigates the frequency of multiple gene rearrangements within the same focus and between different cancer foci. [Lab Invest]

Stemness Markers Characterize IGR-CaP1, A New Cell Line Derived from Primary Epithelial Prostate Cancer
By culturing human prostate primary tumor cells onto human epithelial extra-cellular matrix, researchers successfully selected a new prostate cancer cell line, IGR-CaP1, and clonally-derived subclones. [Exp Cell Res]

HDL and Sphingosine-1-Phosphate Activate Stat3 in Prostate Cancer DU145 Cells via ERK1/2 and S1P Receptors, and Promote Cell Migration and Invasion
In this study, researchers examined the effect of high density lipoprotein and sphingosine-1-phosphate (S1P) on signal transducer and activator of transcription 3 activation in prostate cancer cells and the involvement of S1P receptors in this process in three prostate cancer cell lines (PC-3, LNCaP, and DU145). [Prostate]

CLINICAL RESEARCH

Assessment of Immunological Biomarkers in Patients with Advanced Cancer Treated by Personalized Peptide Vaccination
To investigate immunological biomarkers to predict overall survival of advanced cancer patients under treatment with personalized peptide vaccination, correlations between overall survival and biomarkers, including cytotoxic T lymphocyte and immunoglobulin G responses to the vaccinated peptides, were investigated in 500 advanced cancer patients who received personalized peptide vaccination from October 2000 to October 2008. [Cancer Biol Ther]




INDUSTRY NEWS

Bayer Settles One-A-Day Claims Case
The German drug giant Bayer settled complaints by three states that it had deceptively used the fear of prostate cancer to sell One A Day vitamins without proof the pills could prevent prostate cancer. [The New York Times]



POLICY NEWS

NIH Recovery Act Awards Enable Crucial Health Research Technologies
Thanks to the Recovery Act, more health scientists now will have access to state-of-the-art devices, the National Institutes of Health announced. Through its National Center for Research Resources, NIH has awarded $300 million in shared instrumentation grants.  [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26362) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26363) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26317) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26497) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26499) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26028) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26702) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meetings (FR Doc. 2010-26706) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26390) [National Institutes of Health, United States]

Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-26036) [National Institutes of Health, United States]



EVENTS (Listed by Date)

Queen Mary University of London: 5th UK Cancer Stem Cell Symposium
November 2, 2010
London, United Kingdom

National Cancer Research Institute (NCRI) Conference 2010
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

American Association for Cancer Research (AACR) Tumor Immunology – Basic and Clinical Advances
November 30-December 3, 2010
Miami, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

11th Annual Meeting of the Society of Urologic Oncology (SUO): Extraordinary Opportunities for Discovery
December 8-9, 2010
Bethesda, United States

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

NEW United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us